Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Extra-Label Communication Could Foster Novel Switch NDAs – Industry Attorney

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has several avenues to foster more novel Rx-to-OTC switches, including allowing extra-label communications beyond the packaging, similar to dispensing labeling used by a pharmacist, to be part of an approval.


Related Content

FDA Toots Its Own Horn On Safety Of Marketed Drugs, Imports
Market Exclusivity Needed For Special Condition Switches – Expert
FDA To Tackle Critical Generics Issue In Switch Paradigm Debate
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts